Kelly Peter J, Robinson Laura D, Baker Amanda L, Deane Frank P, McKetin Rebecca, Hudson Suzie, Keane Carol
Illawarra Institute for Mental Health, School of Psychology, University of Wollongong, Australia; Centre for Health Initiatives, University of Wollongong, Australia.
Centre for Health Initiatives, University of Wollongong, Australia.
Addict Behav. 2017 Aug;71:25-30. doi: 10.1016/j.addbeh.2017.02.006. Epub 2017 Feb 10.
The injection of amphetamine is becoming increasingly common. However, there has been a lack of research examining people who inject amphetamine as the primary drug of use, limiting the potential to ensure services address the unique needs of this group. The current study used latent class analysis to identify classes of polydrug use among people who report injecting amphetamine during the past 12months. It also examined differences between classes and drug use patterns, injecting practices, quality of life and psychological distress.
Participants who were attending non-government specialist alcohol and other drug treatment across New South Wales, Australia and had identified amphetamine as their principle drug of concern and reported injecting amphetamine in the previous 12months were included in the current study (N=827). Latent class analysis was performed to identify polydrug profiles of participants.
The large majority of people in the current study (85%) demonstrated low probability of heroin or other opiate use. Three distinct classes of polydrug use were identified: (1) Low-polydrug (n=491), (2) Opiates-polydrug (n=123), and (3) Alcohol-polydrug (n=213). There was a trend for the Low-polydrug class to demonstrate better functioning and safer injecting practices than the Opiates-polydrug and Alcohol-polydrug classes.
The results suggest that the majority of people accessing treatment who inject amphetamine as their primary drug of choice have a low probability of heroin or other opiate use. It is important that future research consider whether traditional harm minimisation strategies are appropriate for people who primarily inject amphetamine.
注射苯丙胺的情况越来越普遍。然而，缺乏针对将注射苯丙胺作为主要使用药物人群的研究，这限制了确保服务满足该群体独特需求的可能性。本研究采用潜在类别分析来确定在过去12个月内报告注射过苯丙胺的人群中的多药使用类别。它还研究了不同类别之间在药物使用模式、注射行为、生活质量和心理困扰方面的差异。
本研究纳入了在澳大利亚新南威尔士州参加非政府专门酒精和其他药物治疗、将苯丙胺确定为主要关注药物且报告在过去12个月内注射过苯丙胺的参与者（N = 827）。进行潜在类别分析以确定参与者的多药特征。
本研究中的绝大多数人（85%）使用海洛因或其他阿片类药物的可能性较低。确定了三种不同的多药使用类别：（1）低多药类（n = 491），（2）阿片类 - 多药类（n = 123），以及（3）酒精 - 多药类（n = 213）。低多药类在功能和注射行为安全性方面比阿片类 - 多药类和酒精 - 多药类有更好表现的趋势。
结果表明，大多数以注射苯丙胺作为主要选择药物接受治疗的人使用海洛因或其他阿片类药物的可能性较低。未来的研究考虑传统的危害最小化策略是否适用于主要注射苯丙胺的人群很重要。
